NEW YORK, Sept. 26 /PRNewswire/ -- The world orthopedic biomaterials market, valued at $4 billion in 2006, is projected to accelerate in tandem with the world's aging population, reaching $8.8 billion in 2012, according to Orthopedic Biomaterials: World Market, a new report by Kalorama Information.
Changing demographics -- particularly a world population that is expected to include 2 billion individuals aged 60 or older by 2050, improved longevity, and higher quality-of-life expectations -- are driving the number of musculoskeletal conditions being diagnosed and treated across the globe. In Europe, 15-20% of all primary care consultations are for musculoskeletal conditions. In the United States, one out of every seven Americans reports a musculoskeletal impairment.
BMP (bone morphogenetic proteins) products, the newest and fastest growing segment in the orthopedic biomaterials market, are expected to increase their sales and holdings in the market during the forecasted period, growing by a CAGR of 25% to $2.9 billion and accounting for 39% of the market. Ceramic product sales, which accounted for 25% of the market in 2006, are projected to grow at a steady CAGR of 10% between 2006-2012 but account for only 21% of the orthopedic materials market by 2012.
"As a result of evolving technology, a number of biomaterials have been introduced to the market over the past several years, all of which are biologically active substances intended to extend, enhance, or even replace autologous graft," notes Anne Anscomb, the report's author. "However, it is the most recent innovations in the orthopedic biomaterials, the development of recombinant bone morphogenetic proteins (BMPs) and synthetic ceramic products, which show the greatest promise in the quest for the perfect orthopedic biomaterial."
Orthopedic Biomaterials: World Market focuses on products and markets
for bone allografts and bone graft substitutes, which include allograft
|SOURCE Kalorama Information|
Copyright©2007 PR Newswire.
All rights reserved